Drug Index


Mechanism :

Binds to and inhibits the activity of fibroblast growth factor 23 (FGF23)

Indication :

  • X-linked hypophosphatemia: in children ≥1 year of age and adults.

Contraindications :

Concomitant use of oral phosphate and active vitamin D analogs; serum phosphorus within or above normal range for age; severe renal impairment or end-stage renal disease

Dosing :

Children and Adolescents ≤17 years:
SC: 0.8 mg/kg/dose every 2 weeks; minimum dose: 10 mg/dose; calculated dose should be rounded to the nearest 10 mg; maximum dose: 90 mg/dose.
Note: Prior to initiating burosumab-twza, Oral phosphate and active vitamin D analogs should be discontinued for at least 1 week. Confirm baseline fasting serum phosphorus level is below the reference range for patient age before initiating burosumab-twza

Adverse Effect :

Headache, dizziness, restless leg syndrome, skin rash, Vit D deficiency, vomiting, tooth abscess, injection site reaction, limb pain, fever, hyperphosphatemia, constipation, antibody development.

Interaction :

Phosphate Supplements: May enhance the adverse/toxic effect of Burosumab-twza.
Vitamin D Analogs: May enhance the adverse/toxic effect of Burosumab-twza.

Hepatic Dose :

No dosage adjustments are recommended.
01/19/2024 02:25:08 Burosumab
Disclaimer: The information given by www.pediatriconcall.com is provided by medical and paramedical & Health providers voluntarily for display & is meant only for informational purpose. The site does not guarantee the accuracy or authenticity of the information. Use of any information is solely at the user's own risk. The appearance of advertisement or product information in the various section in the website does not constitute an endorsement or approval by Pediatric Oncall of the quality or value of the said product or of claims made by its manufacturer.
0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0